SCHEMBL6780304

SCHEMBL6780304

Cc1cc2c(cc1C(=O)NC(=N)NOC=O)S(=O)(=O)Cc1ccc(Cl)cc1-2

nearest known ligand 0.35

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.33
POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6779610 0.93 KMT2A (0.35) KMT2APOLB
SCHEMBL6784567 0.91
SCHEMBL6779341 0.88 KDM4E (0.32) KMT2APOLB
Formic Acid SCHEMBL6780298 0.86 KMT2A (0.33) KMT2APOLB
SCHEMBL14341858 0.85 KMT2A (0.34) KMT2APOLB
SCHEMBL6779923 0.85
SCHEMBL6780092 0.83
SCHEMBL6780390 0.83 THRB (0.32)
SCHEMBL6783272 0.79 KDM4E (0.32)
Formic Acid SCHEMBL6779604 0.78 KMT2A (0.34) KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6730697-B2 FOR USE AS ANTIARRYTHMIC MEDICAMENTS WITH A CARDIOPROTECTIVE COMPONENT FOR PROPHYLAXIS OF AN INFARCTION AND THERAPY OF INFARCTION, AND FOR TREATMENT OF ANGINA PECTORIS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-05-04 US disclosed
US-20030181511-A1 Dihydrothiaphenanthrenecarbonylguanidines: composition, process of making, and use as medicament or diagnostic aid SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2003-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030181511-A1 Dihydrothiaphenanthrenecarbonylguanidines: composition, process of making, and use as medicament or diagnostic aid TNNI3, TNNT2, TNNC1 KMT2A 3990/4885POLB 1009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.